Effects of intravenous beta-blocker(landiolol) infusion after percutaneous coronary intervention for acute myocardial infarction patients.

Effects of intravenous beta-blocker(landiolol) infusion after percutaneous coronary intervention for acute myocardial infarction patients. - Benefit-study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003848

Enrollment

100

Registered

2010-08-01

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Intravenous landiolol infusion Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with first ST elevation myocardial infarction within 12 hours from onset, who underwent successful emergency PCI resulting in TIMI3 flow.

Exclusion criteria

Exclusion criteria: 1)History of old myocardial infarction or CABG 2)Left main coronary artery disease 3)Contraindication of landiolol 4)Contraindication of oral beta-blocker therapy 5)Contraindication of aspirin 6)Systolic blood pressure is 80mmHg or lower 7)Heart rate is 60/min or lower due to atrioventricular block etc. 8)Patients already taking beta-blocker 9)Severe renal and liver dysfunction

Design outcomes

Primary

Measure	Time frame
estimated infarct size	—

Secondary

Measure	Time frame
1)Left ventricular ejection fraction 2)inflammatory markers 3)MACE	—

Countries

Japan

Contacts

Public ContactKentaro Toyama, MD

Saitama Medical Center, Saitama Medical University Division of Cardiology

049-228-3400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026